Angus Dalgleish
23Patents
6h-index
27Co-inventors
69Inventor score
Filing activity: Oct 14, 1994 → Jun 18, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8715677B2 | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy | Emerging Cross-Sectional Technologies | 48 | Active |
| US10758514B2 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour | Human Necessities | 19 | Active |
| US6699483B1 | Cancer treatments | Human Necessities | 13 | Expired |
| US11000486B2 | Combination of cannabinoids in the treatment of leukaemia | Human Necessities | 12 | Active |
| US5935579A | AIDS therapy and vaccine | Mechanical Engineering; Lighting; Heating | 8 | Expired |
| US6972128B1 | Use of human prostrate cell lines in prostate cancer treatment | Human Necessities | 6 | Expired |
| US8841325B2 | Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells | Physics | 2 | Active |
| US9895438B2 | Treatment of cancer with naltrexone | Human Necessities | 2 | Active |
| US12161607B2 | Combination of cannabinoids in the treatment of leukemia | Human Necessities | 1 | Active |
| US8097244B2 | Human prostate cell lines in cancer treatment | Human Necessities | 1 | Active |
| US7438922B2 | Human prostate cell lines in cancer treatment | Human Necessities | 1 | Expired |
| US11351165B2 | Agent that increases the expression of the opioid kappa 1 for the treatment of cancer | Physics | 0 | Active |
| US11885796B2 | Assay to identify anti-cancer agents | Physics | 0 | Active |
| US12029737B2 | Autoimmune therapy | Human Necessities | 0 | Active |
| US11607423B2 | Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer | Human Necessities | 0 | Active |
| US11065245B2 | Priming of cancer cells with low dose naltrexone | Physics | 0 | Active |
| US9200065B2 | Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain | Chemistry; Metallurgy | 0 | Active |
| US9226913B2 | Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof | Human Necessities | 0 | Active |
| US10251949B2 | Stabilized HIV-1 peptide constructs comprising the gp120 C5 domain and gp41 hydrophilic domain | Chemistry; Metallurgy | 0 | Active |
| US12144807B2 | Priming of cancer cells with low dose naltrexone | Physics | 0 | Active |
| US8545835B2 | Human prostate cell lines in cancer treatment | Human Necessities | 0 | Active |
| US8034360B2 | Use of human prostate cell lines in cancer treatment | Human Necessities | 0 | Expired |
| US11304943B2 | Combination for use in the treatment of lung cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.